HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Urokinase-Type Plasminogen Activator (Urokinase)

Subscribe to New Research on Urokinase-Type Plasminogen Activator

A proteolytic enzyme that converts PLASMINOGEN to FIBRINOLYSIN where the preferential cleavage is between ARGININE and VALINE. It was isolated originally from human URINE, but is found in most tissues of most VERTEBRATES.

Also Known As:

Urokinase; Urokinase Type Plasminogen Activator; U-PA; U-Plasminogen Activator; Abbokinase; Kidney Plasminogen Activator; Renokinase; Single-Chain Urokinase-Type Plasminogen Activator; Single Chain Urokinase Type Plasminogen Activator; U Plasminogen Activator; Plasminogen Activator, Urokinase-Type; Urinary Plasminogen Activator

Networked: 5186 relevant articles (240 outcomes, 576 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Rao, Jasti S: 37 articles (05/2014 - 01/2002)
2.	Schmitt, Manfred: 36 articles (04/2015 - 01/2002)
3.	Høyer-Hansen, Gunilla: 26 articles (11/2015 - 05/2002)
4.	Magdolen, Viktor: 25 articles (04/2015 - 01/2002)
5.	Ploug, Michael: 24 articles (12/2015 - 01/2004)
6.	Gondi, Christopher S: 23 articles (09/2013 - 05/2003)
7.	Eugen-Olsen, Jesper: 22 articles (10/2015 - 01/2004)
8.	Yang, Shun-Fa: 22 articles (01/2014 - 07/2004)
9.	Schmitt, M: 22 articles (05/2013 - 01/2000)
10.	Brünner, Nils: 21 articles (11/2015 - 01/2002)

Related Diseases

1.	Thrombosis (Thrombus) 06/05/2012 - "Recurrent episodes of PV and SMV thrombosis were observed in 2 (4.4%) patients at 6 months and 5 years respectively post-discharge and they were treated successfully with urokinase infusion. " 01/01/2002 - "Currently available data fail to provide compelling evidence that newer PAs offer significantly greater efficacy and safety than well-established agents like urokinase when used to treat peripheral vascular thrombosis." 05/01/1995 - "A subsequently developing thrombosis of the left V. femoralis was treated successfully with urokinase. " 05/01/1992 - "These findings suggest that intracoronary urokinase can be effective in reducing early restenosis in patients with angiographic residual thrombus after successful direct PTCA. " 02/01/1991 - "Urokinase was readministered and two showed significant reduction in the thrombus. "
2.	Myocardial Infarction 09/01/1987 - "The efficacy of intracoronary urokinase (UK) in an acute myocardial infarction has not been firmly established in a randomized fashion. " 08/01/1991 - "The clinical efficacy of intravenous fibrinolytic treatment using a moderate dose of urokinase (UK) on acute myocardial infarction (AMI) has not been well evaluated in randomized trials. " 01/01/1997 - "To investigate the influence of different starting time of intravenous urokinase after onset of acute myocardial infarction on the efficacy of thrombolysis. " 01/01/1997 - "Influence of different start time of urokinase therapy after acute myocardial infarction efficacy of thrombolysis. " 05/01/1988 - "Efficacy of intravenous prourokinase and a combination of prourokinase and urokinase in acute myocardial infarction."
3.	Stroke (Strokes) 01/01/2010 - "In this study, combination therapy with low-dose IA urokinase and AMCD is safe and effective after failed IV thrombolysis in patients with acute ischemic stroke. " 09/01/1994 - "Preliminary results suggest that intraarterial urokinase infusion may be effective and safe for treating patients with acute stroke. " 01/01/2010 - "The goal of this study was to assess the feasibility, safety, and efficacy of low-dose intra-arterial (IA) urokinase and aggressive mechanical clot disruption (AMCD) after failure of IV thrombolysis for acute ischemic stroke. " 07/01/2002 - "The purpose of this study was to evaluate the safety and efficacy of local intra-arterial thrombolysis (LIT) using urokinase in patients with acute stroke due to middle cerebral artery (MCA) occlusion. " 09/01/1998 - "The purpose of this study was to evaluate the safety and efficacy of LIT using urokinase in patients with acute ischemic stroke of the anterior or posterior circulation and to determine the influence of clinical and radiological parameters on outcome. "
4.	Neoplasms (Cancer) 04/01/2008 - "After gene array analysis, and confirmation at the protein level, it was discovered that MUC1/sec-expressing tumor cells (DA-3/sec) have a significant reduction in expression of urokinase-type plasminogen activator (uPA) relative to the parental tumor line and tumor cells expressing MUC1/TM. " 07/01/2004 - "Knowledge of their tumor expression levels might be helpful for future individualized therapy protocols, including possible new-targeted therapies based on the interference in the urokinase system." 09/01/2014 - "Currently, there are several studies supporting the role of urokinase-type plasminogen activator (uPA) system in cancer. " 03/01/2006 - "The objectives of the current study were 1) to demonstrate the prognostic relevance of u-PA, u-PAR, and PAI-1 in an independent series; 2) to evaluate u-PA system expression in preoperative biopsy specimens compared with resected tumors; and 3) to evaluate u-PA system expression in intestinal metaplasias and samples with H. " 07/16/1998 - "The urokinase-type plasminogen activator receptor (u-PAR) has been implicated in tumor progression, and previous studies have shown that the expression of this gene is strongly up-regulated by PMA. "
5.	Venous Thrombosis (Deep-Vein Thrombosis) 06/05/2012 - "To evaluate the feasibility and efficacy of urokinase infusion therapy via a transradial approach for transcatheter superior mesenteric artery (SMA) in patients with acute extensive portal and superior mesenteric venous thrombosis. " 02/01/1995 - "Urokinase might be an effective and safe treatment for central venous thrombosis in neonates. " 03/01/2001 - "The thrombolytic efficacy of urokinase correlated with the chronicity of deep venous thrombosis in our model. " 11/01/1998 - "In this study, we establish a protocol for the administration of urokinase for postoperative venous thrombosis. " 10/01/1991 - "The results from this controlled study indicate that a defective release of u-PA may occur in patients with deep vein thrombosis and may have pathogenetic significance. "

Related Drugs and Biologics

1.	Tissue Plasminogen Activator (Alteplase)
2.	Plasminogen Activators (Plasminogen Activator)
3.	Streptokinase
4.	Heparin (Liquaemin)
5.	Plasminogen
6.	Anti-Bacterial Agents (Antibiotics)
7.	Plasminogen Activator Inhibitor 1
8.	Fibrinolytic Agents (Antithrombotic Agents)
9.	Batroxobin
10.	Fibrin

Related Therapies and Procedures

1.	Catheters
2.	Thrombolytic Therapy
3.	Angioplasty (Angioplasty, Transluminal)
4.	Transplants (Transplant)
5.	Stents